Education
Medical school: The University of British Columbia
Residency: Internal Medicine, The University of British Columbia
Fellowship: Bone Barrow Transplantation and Hematology, Stanford University, School of Medicine
Board certification: Internal Medicine · Hematology
Awards
Rell Sunn Award, Moores Cancer Center
Koman Family Presidential Endowed Chair in Cancer Research
UC San Diego Chancellor’s Excellence in Stewardship Award
Blood Cancer Discoveries Grant, Leukemia & Lymphoma Society
Memberships and affiliations
American Society of Hematology
International Society for Stem Cell Research
American Association for Cancer Research
American Association for Cancer Research
Clinical experience
In the consult room Dr. Jamieson concentrates on myeloproliferative neoplasms, acute and chronic leukemias, aplastic anemia, and related marrow disorders, applying precision diagnostics to shape every step of care. New patients undergo comprehensive evaluation that marries cytogenetics, whole-exome sequencing, and flow-cytometry with detailed symptom inventories collected through a bilingual mobile app. Hematopathologists, transfusion experts, social workers, and cardiac-rehabilitation clinicians assemble for daily huddles where laboratory findings match therapeutic sequences covering induction, consolidation, maintenance, and surveillance. Oral targeted agents are paired with pharmacist-led toxicity clinics that monitor adherence, electrolyte shifts, and drug interactions in near real time, while higher-intensity regimens benefit from suites equipped with telepresence so family members can join rounds despite infection-control rules. Supportive-care teams engage early on fertility planning, bone health, and stress management, offering counseling, acupuncture, or mindfulness according to preference. Survivorship begins at diagnosis, scheduling cardiac imaging, endocrinology follow-up, and vaccination updates before treatment ends. A liaison with tribal health services secures culturally appropriate diet guidance, and rural outreach nurses arrange laboratory draws at local clinics to minimize travel. This systematic yet compassionate model replaces uncertainty with clarity, assuring patients that even complex regimens are navigated with expertise and empathy.
Clinical research under Dr. Jamieson’s guidance functions as an extension of routine care through a purpose-built trials office embedded in the hematology clinic. Staff screen every referral against an extensive catalogue of early-phase and adaptive studies exploring spliceosome inhibitors, BET-protein degraders, and next-generation tyrosine-kinase agents crafted to overcome resistance mutations. Electronic-consent platforms permit secure signatures from home, and courier services deliver protocol medications to remote addresses, curbing travel demands. Correlative science captures circulating tumor DNA, single-cell mutation spectra, and cytokine profiles so efficacy assessments reflect both molecular remission and immune recovery. Interim analyses circulate through collaborative networks in near real time, enabling community oncologists to adopt promising regimens via expanded-access pathways. Dedicated nurse navigators manage logistics, side-effect diaries, and financial counseling, while health economists track cost data to inform payer policy after approval. Telehealth check-ins monitor fatigue, mood, and adherence, and translation services cover multiple dialects so language never stands between a participant and full study comprehension. This seamless connection between discovery and standard practice lets patients weigh scientifically grounded options while feeling fully supported throughout the trial journey.
Dr. Jamieson’s horizon scanning embraces modalities poised to rewrite blood-cancer care, from programmable RNA editors and CRISPR-enabled autologous stem-cell correction to radioligand therapies that ferry beta-emitting isotopes straight to marrow niches harboring minimal disease. Her laboratory engineers bioprinted bone-marrow organoids that mimic oxygen gradients and stromal interactions, enabling rapid screening of drug pairs before patients receive a single dose. Collaborations with aerospace engineers examine how microgravity alters leukemic metabolism, guiding ground-based efforts to disable metabolic plasticity and sensitize stem cells to therapy. She serves on guideline committees advocating for cell-free DNA and RNA monitoring that triggers pre-emptive treatment at the first molecular hint of relapse, reducing reliance on repeat biopsies. Policy work promotes reimbursement frameworks that keep innovative modalities from widening disparities, while education materials use plain language and culturally adapted imagery to explain risks and benefits. Early compassionate-use requests processed through her office already employ this molecular-trigger philosophy, offering vetted access to investigational agents when conventional options provide limited prospects for lasting remission. By weaving laboratory imagination, technological partnership, and transparent dialogue into a single forward-looking strategy, Dr. Jamieson equips patients with realistic hope and assurance that better options may be just ahead.